The Regulatory Mix

Sponsored by Tailwind Pharma, LLC

Welcome to The Regulatory Mix — your go-to briefing for FDA guidances, cGMPs, and the real-world events that shape pharmaceutical quality. This podcast is human-curated but AI-assisted, crafted for regulatory professionals, quality leaders, and curious minds who want to stay ahead in an ever-evolving compliance landscape. Each episode breaks down: 🔍 Key FDA guidances and current Good Manufacturing Practices ⚠️ Recent FDA warning letters and enforcement trends 💡 Practical insights from real-world pharma and compounding cases Whether you’re a seasoned expert or new to the quality game, The Regulatory Mix turns complex regulatory language into actionable takeaways — keeping you sharp, informed, and audit-ready. Follow along and join the conversation — because compliance isn’t just a checkbox. It’s a mindset. #RegulatoryAffairs #FDACompliance #PharmaQuality #cGMP #Podcast #TheRegulatoryMix #Compounding #DrugManufacturing Disclaimer: This podcast is for informational and entertainment purposes only. Interpretations of hosts may differ from official regulations or final agency positions. Always consult a qualified regulatory professional for compliance decisions. Sponsored by Tailwind Pharma, LLC https://www.tailwindconsult.com

  1. 2 DAYS AGO

    First-Cycle or Fall Behind: Strategic Leadership in ANDA Execution

    On this episode of The Regulatory Mix, the hosts break down why ANDA success is not just a regulatory milestone, but a leadership test. Winning in the generic drug space requires far more than filing a technically complete application. It demands enterprise-level coordination across bioequivalence, quality, labeling, intellectual property, manufacturing, facilities, and regulatory affairs, all moving in sync toward one commercial objective: approval with launch readiness on day one. The discussion centers on a simple but often overlooked reality: an ANDA is only as strong as its weakest link. A formulation issue, a mislabeled certification, a delayed DMF amendment, or a facility that is not inspection-ready can each stop the entire application. The hosts explain why the most costly failures are usually not scientific surprises, but predictable breakdowns in cross-functional handoffs, poor dependency management, and weak program ownership. This episode also explores the financial stakes behind ANDA strategy. First-cycle approval and 180-day exclusivity are not merely regulatory achievements—they are enterprise value drivers that can determine market share, pricing power, and portfolio return. Leadership teams that understand Orange Book timing, Paragraph IV risk, tentative approval strategy, and labeling carve-outs are better positioned to protect value and avoid avoidable delays that quietly erode commercial opportunity. The hosts also highlight the importance of FDA engagement under the GDUFA framework, emphasizing that disciplined, credible interactions with the Agency are a performance advantage. Strong responses to information requests, clean management of unsolicited amendments, and accurate facility and Form 356h information all shape not only the fate of a single ANDA, but the credibility of the broader portfolio. The takeaway is clear: ANDAs should be managed as integrated business assets, not isolated regulatory projects. In this environment, strong governance compounds value, while weak alignment destroys it quietly through delays, lost exclusivity, and missed launch opportunities. Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

    18 min

  2. 15 APR

    The Automation Trap: AI in Pharma, Regulatory Risk, and the Fight to Preserve Critical Thinking

    On this episode of The Regulatory Mix, we examine the collision between AI, pharmaceutical manufacturing, and regulatory accountability. As AI moves into Current Good Manufacturing Practice (CGMP) environments, the central question is whether firms can use it without weakening quality oversight and compliance discipline. The Cost of Over-Reliance A recent FDA Warning Letter issued to Purolea Cosmetics Lab serves as a case study for the dangers of unsupervised AI. The firm used AI to generate drug product specifications, procedures, and production records without adequate human review. This led to critical failures: -The firm was unaware of process validation requirements because its AI agent failed to mention them. -The Quality Unit (QU) failed to oversee CGMP compliance or review batch records. -Basic sanitary conditions were neglected, leading to facility contamination. FDA AI Credibility Framework FDA draft guidance introduces a risk-based credibility assessment framework. Model risk is determined by: * Model Influence: The weight of the AI data relative to other evidence. * Decision Consequence: The severity of a wrong decision. * Context of Use (COU): High-risk scenarios, like automated patient monitoring, require the most rigorous validation. The Erosion of Critical Thinking Research on 319 knowledge workers reveals that generative AI is shifting human effort from problem-solving toward verification and stewardship. Key findings include: * Confidence Paradox: High confidence in AI often leads to less critical thinking. * Stewardship Shift: Cognitive work is moving from material production to overseeing AI outputs. * Skill Atrophy: Automation may deprive users of the practice needed to handle complex exceptions. The Bottom Line In regulated industries, AI is an assistive tool, not a substitute for human expertise. Accountability cannot be automated; firms remain responsible for ensuring the safety and quality of every product. REFERENCE LINKS Purolea Cosmetics Lab Warning Letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purolea-cosmetics-lab-722591-04022026 FDA Draft Guidance (January 2025): https://www.fda.gov/media/184830/download Research: AI and Critical Thinking (CHI 25): https://www.microsoft.com/en-us/research/wp-content/uploads/2025/01/lee_2025_ai_critical_thinking_survey.pdf Disclaimer: The views expressed in this episode are personal opinions for educational purposes and do not constitute legal, regulatory, or medical advice.

    21 min

  3. 12 APR

    Track, Trace, Trust: DSCSA and the Final Push to Secure America’s Drug Supply

    On this episode of The Regulatory Mix, the hosts break down the Drug Supply Chain Security Act and the long build toward a fully interoperable system for tracing prescription drugs across the U.S. supply chain. What began in 2013 as a framework to protect patients from counterfeit, stolen, contaminated, and otherwise dangerous drugs has evolved into one of the most operationally significant compliance mandates affecting manufacturers, wholesale distributors, dispensers, repackagers, and 3PLs. At the center of the discussion is the four-part structure of DSCSA: authorized trading partners, product serialization, transaction tracing, and the verification and handling of suspect or illegitimate product. The episode explains how these pillars work together to create accountability across each handoff in the supply chain, and why the shift from lot-level tracing to package-level electronic tracing represents such a major leap in practice. The hosts also examine the “enhanced drug distribution security” phase, including the move to secure electronic exchange of transaction data and the need for systems that can rapidly trace product back through the distribution chain during recalls, investigations, or counterfeit events. The FDA’s stabilization period helped industry transition, but the larger message remains clear: the era of fragmented tracing is ending, and trading partners are expected to operate in a far more connected and transparent system. This episode also highlights how DSCSA is no longer just a statutory requirement sitting in the background. Recent enforcement and counterfeit-drug events show exactly why authorized sourcing, serialization, and product verification matter. As implementation matures, DSCSA is becoming a real-world test of whether firms can combine compliance, technology, and operational discipline to protect both product integrity and patient safety. Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

    11 min

  4. 2 APR

    Beyond Biosimilarity: The Push for Interchangeability

    On this episode of The Regulatory Mix, the hosts break down the FDA’s regulatory framework for biosimilar and interchangeable biological products under the Biologics Price Competition and Innovation Act. The episode explains how the 351(k) pathway allows sponsors to rely in part on the FDA’s prior finding for a reference product, while still requiring a strong demonstration of biosimilarity through analytical, nonclinical, and clinical evidence. It also highlights the higher evidentiary bar for interchangeability, including the ability to support pharmacy-level substitution subject to state law. The discussion also covers the business and operational side of development, including BsUFA and PDUFA review timelines, the role of the Purple Book, reference product exclusivity, and how FDA’s review program is designed to improve transparency and increase first-cycle approvals. The episode walks through practical considerations for sponsors, including pediatric requirements, use of non-U.S. comparators, and the scientific bridge needed to support global development strategies. Finally, the episode turns to post-approval lifecycle management, explaining how manufacturing changes for licensed biologics are handled through PAS, CBE, and annual report categories, and why comparability exercises remain central to demonstrating that quality, purity, and potency are maintained after change. This is a useful listen for anyone working in biosimilar development, regulatory affairs, CMC, or quality oversight. Disclaimer: The views discussed are for educational and informational purposes only and do not constitute legal, regulatory, or professional advice. Any opinions expressed are personal and do not reflect the views of any current or former employer, agency, or client.

    16 min

  5. 29 MAR

    Show Me the Evidence: FDA’s New Era of Visual Enforcement

    On this episode of The Regulatory Mix, we break down a pivotal shift in FDA enforcement strategy—highlighted by the 2026 Warning Letter issued to Patcos Cosmetics, where the Agency embedded inspection photographs directly into the letter. This move signals a transition toward radical transparency, where visual evidence is now used to document insanitary conditions and elevate the reputational and regulatory consequences of non-compliance. We explore how this development aligns with broader enforcement trends, including the reorganization of ORA into OII, a 50% surge in Warning Letters, and increased focus on data integrity, global supply chains, and inspection authority—particularly the expectation that firms allow photography during inspections. This episode unpacks what this means operationally: from facility maintenance and quality culture to the limitations of remote audits and the growing risk of import alerts when inspections are restricted. The message is clear—compliance is no longer just written, it’s visual, immediate, and publicly shareable. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/patcos-cosmetics-pvt-ltd-718220-03122026 Disclaimer: The views expressed are for informational and educational purposes only and do not constitute legal, regulatory, or professional advice. They do not reflect the views of any current or former employers or clients.

    15 min

  6. 22 MAR

    FDA Goes Real-Time: AEMS, Sentinel 3.0, and the Future of Surveillance

    On this episode of The Regulatory Mix, we break down the FDA’s March 2026 modernization push—anchored by the launch of the Adverse Event Monitoring System (AEMS) and the expansion of Sentinel 3.0. These initiatives mark a structural shift toward a real-time, AI-enabled regulatory ecosystem, consolidating legacy systems like FAERS, VAERS, and MAUDE into a single unified platform. We explore how AEMS is designed to improve data quality, streamline reporting, and enhance signal detection across all FDA-regulated products—while also unpacking its critical limitations, including lack of causality and data verification challenges. On the active surveillance side, Sentinel 3.0 expands beyond drugs into devices and immunization data, with governance moving to the Office of the Commissioner and new capabilities like studies-as-a-service and cloud-based analytics. Finally, we examine the broader FDA Wrap modernization narrative—highlighting efficiency gains, cost savings, and the growing tension between innovation and stakeholder skepticism around performance, funding, and institutional tone. This is a foundational shift in how the FDA sees—and acts on—post-market risk. Watch the full episode: [https://youtu.be/basc7IelnY4](https://youtu.be/basc7IelnY4) Disclaimer: This content is for informational and educational purposes only and reflects analysis and interpretation of publicly available regulatory information. It does not constitute legal or regulatory advice.

    13 min

  7. 19 MAR

    Endotoxins Rewritten: FDA Retires 1987 and Resets the Rules on Pyrogen Testing

    On this episode of The Regulatory Mix, we break down the FDA’s updated guidance on pyrogen and endotoxin testing—a quiet but significant reset of long-standing industry practices. The Agency has formally withdrawn its 1987 LAL validation guidance and now emphasizes calculation-based approaches aligned with current USP chapters and AAMI ST72. This shift signals that legacy methods for setting endotoxin limits, validation, and sampling are no longer sufficient without modern justification. We explore how the FDA continues to position the Limulus Amebocyte Lysate (LAL) test as the primary method, while still requiring the rabbit pyrogen test in cases involving non-endotoxin pyrogens or unresolved product interference. The guidance also opens the door for alternative methods like the Monocyte Activation Test, but only when supported by robust validation demonstrating equivalence or superiority to compendial methods. Operational expectations are sharper than ever. Sampling must be scientifically sound and dynamic, pooling strategies must account for adjusted Maximum Valid Dilution (MVD), and failures at MVD without assignable cause will likely result in batch rejection. The FDA also reinforces a shift toward quantitative, risk-based approaches under Quality by Design—moving endotoxin control upstream into process understanding rather than relying solely on final product testing. The takeaway is clear: this is not new science—it’s a push for modern discipline. Firms must calculate, validate, trend, and justify their endotoxin control strategies across the full product lifecycle. Link to new guidance: https://www.fda.gov/media/83477/download Disclaimer: This content is for informational and educational purposes only and does not constitute regulatory or legal advice. Firms should evaluate applicability based on product-specific risk and current regulatory requirements.*

    10 min

  8. 15 MAR

    GLP-1 Wars: Peptides, Kennedy, and the FDA’s Ever-Changing Line in the Sand

    On this episode of The Regulatory Mix, we explore the rapidly shifting regulatory landscape surrounding peptide therapies, compounded GLP-1 medications, and the legal framework that governs pharmaceutical compounding in the United States. As demand for GLP-1 drugs such as semaglutide and tirzepatide continues to surge, regulatory scrutiny has intensified following the FDA’s decision to remove these products from the drug shortage list, a move that significantly changes the legal footing for many compounding operations. At the center of the discussion is the statutory structure created by the Drug Quality and Security Act (DQSA), which distinguishes between traditional compounding under Section 503A and outsourcing facilities operating under Section 503B. While 503A pharmacies compound patient-specific prescriptions primarily under state oversight, 503B outsourcing facilities operate under federal CGMP requirements and FDA inspection authority. The key legal constraint affecting both groups is the prohibition against producing drugs that are “essentially copies” of commercially available products — unless those products appear on the FDA drug shortage list. With GLP-1 therapies now removed from that shortage list, the regulatory “safe harbor” that allowed large-scale compounding of these products has effectively disappeared. This shift places compounding entities, including large telehealth-driven platforms, into potential legal conflict with pharmaceutical manufacturers seeking to protect patented, FDA-approved therapies. At the same time, renewed public discussion around peptides — amplified by high-profile media appearances from figures such as Robert F. Kennedy Jr. on the Joe Rogan Experience is expanding consumer awareness and political debate around peptide therapies, further complicating the regulatory environment. The episode also revisits the safety history that shaped modern compounding oversight. Catastrophic events such as the 2012 New England Compounding Center (NECC) fungal meningitis outbreak, which resulted in more than 60 deaths and hundreds of illnesses, drove the creation of the DQSA and the 503B outsourcing facility pathway. These events remain a critical reminder of why FDA distinguishes between approved drugs, which undergo rigorous clinical evaluation, and compounded products prepared from bulk drug substances. Finally, we examine the limited scope of the FDA’s Bulk Drug Substances (BDS) lists, which determine whether certain ingredients can legally be used in compounded medications when they are not part of approved drugs or shortage exceptions. With only a small number of substances currently permitted for routine compounding use, the pathway for adding new peptide ingredients remains complex and highly regulated. As peptide therapies continue to capture public attention and commercial demand grows, the intersection of politics, patient access, intellectual property, and federal drug law will likely define the next chapter of compounding regulation. If you enjoyed the episode, give us a rating on Apple Podcasts, check out the video version on YouTube, and share it with colleagues or on LinkedIn. Read 🎧 Listen 👀 Follow 🔁 Share — the mix keeps moving. Disclaimer The content discussed in this podcast is for educational and informational purposes only and reflects general regulatory concepts related to FDA oversight and pharmaceutical manufacturing. It does not constitute legal advice, regulatory advice, or official guidance from the U.S. Food and Drug Administration. The views expressed are those of the host and do not represent the positions of any current or former employer or government agency.

    13 min
See All (92)

About

Welcome to The Regulatory Mix — your go-to briefing for FDA guidances, cGMPs, and the real-world events that shape pharmaceutical quality. This podcast is human-curated but AI-assisted, crafted for regulatory professionals, quality leaders, and curious minds who want to stay ahead in an ever-evolving compliance landscape. Each episode breaks down: 🔍 Key FDA guidances and current Good Manufacturing Practices ⚠️ Recent FDA warning letters and enforcement trends 💡 Practical insights from real-world pharma and compounding cases Whether you’re a seasoned expert or new to the quality game, The Regulatory Mix turns complex regulatory language into actionable takeaways — keeping you sharp, informed, and audit-ready. Follow along and join the conversation — because compliance isn’t just a checkbox. It’s a mindset. #RegulatoryAffairs #FDACompliance #PharmaQuality #cGMP #Podcast #TheRegulatoryMix #Compounding #DrugManufacturing Disclaimer: This podcast is for informational and entertainment purposes only. Interpretations of hosts may differ from official regulations or final agency positions. Always consult a qualified regulatory professional for compliance decisions. Sponsored by Tailwind Pharma, LLC https://www.tailwindconsult.com

Information

  • Creator
    Sponsored by Tailwind Pharma, LLC
  • Years Active
    2024 - 2026
  • Episodes
    92
  • Show Website
    The Regulatory Mix

You Might Also Like